开云app官网登录入口网页版-官方正版

#去势抵抗性前列腺癌#

112篇内容 | 2490人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2221934, encodeId=f44a22219344c, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a> <a href='/topic/show?id=827ce70573c' target=_blank style='color:#2F92EE;'>#紫杉类药物#</a> <a href='/topic/show?id=339211821836' target=_blank style='color:#2F92EE;'>#雄激素受体通路抑制剂#</a>, objectTitle=Nature Medicine：ProBio平台：前列腺癌精准治疗的新纪元, objectType=article, longId=838423, objectId=8dba838423cb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240821/1724205043049_8538692.jpg, objectUrl=/article/show_article.do?id=8dba838423cb, replyNumber=0, likeNumber=46, createdTime=2024-08-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8dba838423cb, moduleTitle=Nature Medicine：ProBio平台：前列腺癌精准治疗的新纪元, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8dba838423cb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1342189, encodeId=2944134218945, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, objectType=article, longId=738674, objectId=c94ce38674b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c94ce38674b5, replyNumber=0, likeNumber=0, createdTime=2022-09-10, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c94ce38674b5, moduleTitle=Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c94ce38674b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342188, encodeId=98bc134218856, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=729045, objectId=c007e2904512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c007e2904512, replyNumber=0, likeNumber=122, createdTime=2022-06-11, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c007e2904512, moduleTitle=Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c007e2904512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342187, encodeId=3e4e134218e46, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, objectType=article, longId=728547, objectId=db53e28547ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db53e28547ba, replyNumber=0, likeNumber=100, createdTime=2022-06-04, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db53e28547ba, moduleTitle=Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=db53e28547ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342186, encodeId=dc6d134218617, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响, objectType=article, longId=727118, objectId=4bc9e2711830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bc9e2711830, replyNumber=0, likeNumber=96, createdTime=2022-05-18, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bc9e2711830, moduleTitle=Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4bc9e2711830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342185, encodeId=6d5a134218552, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌, objectType=article, longId=299388, objectId=6e0a29938862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0a29938862, replyNumber=0, likeNumber=82, createdTime=2022-02-23, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0a29938862, moduleTitle=Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6e0a29938862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342184, encodeId=2775134218427, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=295173, objectId=79422951e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79422951e301, replyNumber=0, likeNumber=0, createdTime=2022-02-07, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79422951e301, moduleTitle=Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=79422951e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342183, encodeId=36d3134218350, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展, objectType=article, longId=291931, objectId=c5962919319b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5962919319b, replyNumber=0, likeNumber=83, createdTime=2021-12-17, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5962919319b, moduleTitle=益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c5962919319b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342182, encodeId=8722134218241, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, objectType=article, longId=221370, objectId=59592213e0c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59592213e0c8, replyNumber=0, likeNumber=0, createdTime=2021-12-02, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59592213e0c8, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=59592213e0c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342181, encodeId=aa2b13421815e, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查, objectType=article, longId=220484, objectId=e3c4220484eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3c4220484eb, replyNumber=0, likeNumber=79, createdTime=2021-11-18, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3c4220484eb, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e3c4220484eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342180, encodeId=ffe3134218048, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响, objectType=article, longId=220037, objectId=996422003ee6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996422003ee6, replyNumber=0, likeNumber=110, createdTime=2021-11-11, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996422003ee6, moduleTitle=Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=996422003ee6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342179, encodeId=358e13421e9bd, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查, objectType=article, longId=218948, objectId=70c9218948f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70c9218948f1, replyNumber=0, likeNumber=87, createdTime=2021-10-22, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70c9218948f1, moduleTitle=Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=70c9218948f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342178, encodeId=0d8113421e871, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？ , objectType=article, longId=217567, objectId=1e9121e567e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9121e567e8, replyNumber=0, likeNumber=75, createdTime=2021-09-25, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9121e567e8, moduleTitle=Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？ , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1e9121e567e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342177, encodeId=1da013421e7a8, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？, objectType=article, longId=217432, objectId=267021e43210, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267021e43210, replyNumber=0, likeNumber=77, createdTime=2021-09-24, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267021e43210, moduleTitle=Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=267021e43210)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342176, encodeId=9c2613421e665, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌, objectType=article, longId=217362, objectId=4a1721e36230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a1721e36230, replyNumber=0, likeNumber=142, createdTime=2021-09-22, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a1721e36230, moduleTitle=NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4a1721e36230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342175, encodeId=49c513421e504, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=79, createdTime=2021-08-13, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342174, encodeId=c79f13421e46a, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理, objectType=article, longId=215284, objectId=f0ec21528430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0ec21528430, replyNumber=0, likeNumber=105, createdTime=2021-08-06, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0ec21528430, moduleTitle=J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f0ec21528430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342173, encodeId=c63213421e341, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究 , objectType=article, longId=215282, objectId=daad21528299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daad21528299, replyNumber=0, likeNumber=68, createdTime=2021-08-06, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daad21528299, moduleTitle=Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究 , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=daad21528299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342172, encodeId=4a2513421e263, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, objectType=article, longId=215209, objectId=93d5215209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d5215209e6, replyNumber=0, likeNumber=101, createdTime=2021-08-04, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d5215209e6, moduleTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=93d5215209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1342171, encodeId=8baa13421e112, content=<a href='/topic/show?id=da143e23485' target=_blank style='color:#2F92EE;'>#去势抵抗性前列腺癌#</a>, objectTitle=Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关, objectType=article, longId=215168, objectId=549b215168d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=549b215168d2, replyNumber=0, likeNumber=105, createdTime=2021-08-03, rootId=0, userName=ms1948154235210413, userId=464b2500186, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=549b215168d2, moduleTitle=Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=549b215168d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

去势抵抗性前列腺癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#前列腺癌# #去势抵抗性前列腺癌# #紫杉类药物# #雄激素受体通路抑制剂#

Nature Medicine：ProBio平台：前列腺癌精准治疗的新纪元

2024-08-22发表于上海

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：奥拉帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌的患者报告的预后

2022-09-10

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：卡博替尼联合阿托珠单抗治疗转移性去势抵抗性前列腺癌

2022-06-11

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Nature Cancer：仁济医院高维强教授发现Gremlin1可能是去势抵抗性前列腺癌治疗新靶点

2022-06-04

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur J Cancer：二甲双胍和他汀类药物对转移性去势抵抗性前列腺癌患者预后的影响

2022-05-18

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Clin Cancer Res：瑞博西尼联合多西他赛治疗转移性去势抵抗性前列腺癌

2022-02-23

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：尼拉帕利在DNA修复基因缺陷的转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-02-07

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

益普生直击2020 EAU 周芳坚教授：去势抵抗性前列腺癌新近进展

2021-12-17

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性

2021-12-02

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur Urol：转移去势抵抗性前列腺癌中，激素治疗与化疗获益的预测性基因组生物标志物调查

2021-11-18

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur J Cancer：DNA损伤修复状态对卡巴他赛治疗转移性去势抵抗性前列腺癌的活性的影响

2021-11-11

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Int J Urol：转移去势抵抗性前列腺癌中，一线治疗生存结果的预测因素调查

2021-10-22

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur Urol：Avelumab联合SABR是否能促进转移去势抵抗性前列腺癌的疗效？

2021-09-25

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Clin Cancer Res：检出cfDNA低频突变对去势抵抗性前列腺癌究竟有无意义？

2021-09-24

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

NEJM：177Lu-PSMA-617靶向放疗治疗转移性去势抵抗性前列腺癌

2021-09-22

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

2021-08-13

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

J Urol：美国真实世界中对转移去势抵抗性前列腺癌患者的管理

2021-08-06

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur Urol：卡巴他赛与阿比特龙或恩杂鲁胺在老年转移性去势抵抗性前列腺癌患者中的疗效和安全性比较研究

2021-08-06

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-08-04

ms1948154235210413 (审核中...)

前往app查看评论内容

#去势抵抗性前列腺癌#

Br J Cancer：转移性去势抵抗性前列腺癌中雄激素受体基因扩增状态与177Lu-PSMA-617治疗抗性相关

2021-08-03

科室
- - 订阅+
  - 更多科室
工具
服务